Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.64 |
| ▸ | CASP3 | P42574 | 2/20 | 0.58 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.58 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.58 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.58 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | SCD | O00767 | 5/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29432459 | 1.00 | CNR1 (0.64) | CNR1CASP3SENP8SENP7SENP6 | |
| SCHEMBL13778842 | 0.89 | CNR1 (0.72) | CNR1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4252873 | 0.85 | CNR1 (0.63) | CNR1NPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL4253987 | 0.82 | MAOA (0.61) | CNR1CASP3SENP8SENP7SENP6 | |
| SCHEMBL4253000 | 0.80 | CASP3 (0.61) | CASP3SENP8SENP7SENP6LRRK2 | |
| SCHEMBL4918014 | 0.79 | CNR1 (1.00) | CNR1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL30944353 | 0.77 | CNR1 (0.70) | CNR1CASP3SENP8SENP7SENP6 | |
| SCHEMBL28529053 | 0.77 | CNR1 (0.70) | CNR1CASP3SENP8SENP7SENP6 | |
| SCHEMBL17251803 | 0.76 | CASP3 (0.65) | CASP3SENP8SENP7SENP6LRRK2 | |
| SCHEMBL29532955 | 0.76 | CASP3 (0.65) | CASP3SENP8SENP7SENP6LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170914-A1 | Cermide Kinase Modulation | BORNANCIN FREDERIC | 2009-07-02 | — | — | US | claimed |
| EP-2004617-A2 | CERAMIDE KINASE MODULATION | Novartis AG (CH) | 2008-12-24 | — | — | EP | claimed |
| WO-2007112914-A2 | CERAMIDE KINASE MODULATION | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20090170914-A1 | Cermide Kinase Modulation | BORNANCIN FREDERIC | 2009-07-02 | — | — | US | disclosed |
| US-20090170914-A1 | Cermide Kinase Modulation | BORNANCIN FREDERIC | 2009-07-02 | — | — | US | disclosed |
| EP-2004617-A2 | CERAMIDE KINASE MODULATION | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007112914-A2 | CERAMIDE KINASE MODULATION | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170914-A1 | Cermide Kinase Modulation | CERS2, CHKB, SPHK2 | CNR1 111/4885CASP3 2265/4885SENP8 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.